Fidaxomicin (OPT-80)是一种口服有效的大环抗生素,通过抑制RNA聚合酶发挥抗菌作用。它具有窄谱活性,对艰难梭菌作用显著,可用于相关感染研究。
|
英文别名 (English Synonym) |
Fidaxomicin |
|
中文名称 (Chinese Name) |
非达霉素 |
|
靶点 (Target) |
DNA/RNA Synthesis |
|
通路 (Pathway) |
Cell Cycle/DNA Damage |
|
CAS号 (CAS NO.) |
873857-62-6 |
|
分子式 (Formula) |
C52H74Cl2O18 |
|
分子量 (Molecular Weight) |
1058.04 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, Emery J, Louie T. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading). 2010 Nov,156(Pt 11):3354-3359. doi: 10.1099/mic.0.042010-0. Epub 2010 Aug 19. PMID: 20724385.[2]Ackermann G, Löffler B, Adler D, Rodloff AC. In vitro activity of OPT-80 against Clostridium difficile. Antimicrob Agents Chemother. 2004 Jun,48(6):2280-2. doi: 10.1128/AAC.48.6.2280-2282.2004. PMID: 15155234, PMCID: PMC415632.
